التفاصيل البيبلوغرافية
| العنوان: |
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. |
| المؤلفون: |
Marin, Elba, Teixido, Cristina, Carmona-Rocha, Elena, Reyes, Roxana, Arcocha, Ainara, Viñolas, Nuria, Rodríguez-Mues, MªCarmen, Cabrera, Carlos, Sánchez, Marcelo, Vollmer, Ivan, Castillo, Sergi, Muñoz, Silvia, Sullivan, Ivana G., Rodriguez, Adela, Garcia, Mireia, Alos, Silvia, Jares, Pedro, Martinez, Antonio, Prat, Aleix, Molina-Vila, Miguel Ángel |
| المصدر: |
Cancers; May2020, Vol. 12 Issue 5, p1124, 1p |
| مصطلحات موضوعية: |
LUNG cancer diagnosis, DNA analysis, RNA analysis, BIOLOGICAL assay, CANCER patients, CANCER patient medical care, CONFIDENCE intervals, EVALUATION of medical care, GENETIC mutation, SURVIVAL, GENOMICS, DESCRIPTIVE statistics, GENOTYPES |
| مستخلص: |
Personalized medicine is nowadays a paradigm in lung cancer management, offering important benefits to patients. This study aimed to test the feasibility and utility of embedding two multiplexed genomic platforms as the routine workup of advanced non-squamous non-small cell lung cancer (NSCLC) patients. Two parallel multiplexed approaches were performed based on DNA sequencing and direct digital detection of RNA with nCounter® technology to evaluate gene mutations and fusions. The results were used to guide genotype-directed therapies and patient outcomes were collected. A total of 224 advanced non-squamous NSCLC patients were prospectively included in the study. Overall, 85% of samples were successfully characterized at DNA and RNA levels and oncogenic drivers were found in 68% of patients, with KRAS, EGFR, METΔex14, BRAF, and ALK being the most frequent (31%, 19%, 5%, 4%, and 4%, respectively). Among all patients with complete genotyping results and follow-up data (n = 156), the median overall survival (OS) was 1.90 years (confidence interval (CI) 95% 1.69–2.10) for individuals harbouring an actionable driver treated with a matched therapy, compared with 0.59 years (CI 95% 0.39–0.79) in those not eligible for any targeted therapy and 0.61 years (CI 95% 0.12–1.10) in patients with no drivers identified (p < 0.001). Integrating DNA and RNA multiplexing technologies into the routine molecular testing of advanced NSCLC patients is feasible and useful and highlights the necessity of widespread integrating comprehensive molecular diagnosis into lung cancer care. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder